Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of mirtazapine on anxiety and depression in patients with malignant tumors
ChiCTR2300073945Phase 4Not yet recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mirtazapine in anxiety disorder and major depressive disorder (MDD), sponsored by Shengjing Hospital of China Medical University. Primary endpoints: Hamilton Anxiety Scale score and Hamilton Depression Scale score. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
mirtazapine
03
Conditions
anxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2300073945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073945.